CXXIF · C21 Investments Inc.
Price & Indicators
Up next
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders NeutralIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CXXIF
this stock
C21 Investments Inc.
|
$31.41M | -31.2% | +8.3% | — | 0.1% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd./ADR
|
$66.37B | — | — | — | 0.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$57.58B | +16.9% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$47.69B | -1.4% | — | — | 0.0% |
|
HLN
Haleon plc
|
$44.35B | -0.4% | — | — | 0.3% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- % held
- 0.1%
- Net QoQ
- +75.0K sh
- Top holder
- GOFEN & GLOSSBERG LLC /IL/
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CXXIF | -2.3% | +29.1% | -11.5% | +30.4% | -31.3% |
| SPY | -1.4% | +3.6% | +11.6% | +2.5% | +12.3% |
| vs SPY | -1.0% | +25.5% | -23.0% | +27.9% | -43.5% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.